ARVN
ARVINAS, INC.
Key Financials
Net Income
$-80800000
↑ 59.4%
Operating Income
$-118500000
↑ 52.6%
Revenue
$262.6M
↓ 0.3%
Total Assets
$717.9M
↓ 34.2%
Shareholders' Equity
$433.9M
↓ 22.8%
EPS (Diluted)
$-1.14
↑ 58.8%
Cash & Equivalents
$142.9M
↑ 42.2%
Total Liabilities
$284.0M
↓ 46.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 5/20/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| 10-Q | 5/11/2026 | View on SEC |
| 144 | 5/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ARVN |
| Company Name | ARVINAS, INC. |
| CIK | 1655759 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 203-535-1456 |